1-20 of 82
Toby A. Eyre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank

Sarah Mant, Georgina Naylor, Nicola Crosbie, Sree Aroori, Mark J Bishton, Kristian Bowles, Safia Dawi, Toby A. Eyre, Wendy Ingram, Abigail Martin, Christopher McNamara, Melanie Oates, Andrew Pettitt, Claire Scully, Brian Wainman, Mark Warner, Simon Rule, David John Lewis
Journal: Blood
Blood (2024) 144 (Supplement 1): 1641.
https://doi.org/10.1182/blood-2024-209701
Published: 2024
Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Nicole Lamanna, Jennifer R. Brown, Chaitra S. Ujjani, Toby A. Eyre, Beenish Manzoor, Nilanjan Ghosh, Lindsey Roeker, Matthew S. Davids, Catherine C Coombs, Alan P Skarbnik, Brian T. Hill, Hande H. Tuncer, Lori A. Leslie, Joanna M. Rhodes, Isabelle Fleury, Paul M Barr, Nnadozie Emechebe, Nicolas Martinez-Calle, Christopher E. Jensen, Yun Choi, Dureshahwar Jawaid, Laurie K Pearson, Meghan C. Thompson, Steven E Marx, Wendy J. Sinai, Frederick Lansigan, Bita Fakhri, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4625.
https://doi.org/10.1182/blood-2024-205223
Published: 2024
Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart
Journal: Blood
Blood (2024) 144 (Supplement 1): 745.
https://doi.org/10.1182/blood-2024-194357
Published: 2024
Journal Articles

Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Tamar Tadmor, Toby A. Eyre, Ohad Benjamini, Arvind Chaudhry, Juan Shen, Siyang Leng, Mohammed Z. H. Farooqui, David Lavie
Journal: Blood
Blood (2024) 144 (Supplement 1): 1875.2.
https://doi.org/10.1182/blood-2024-198731
Published: 2024
Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2024-194748
Published: 2024
Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Talha Munir, Abraham Mullasseril Varghese, Adrian Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankara Paneesha, Christopher P Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, Prof. John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Anna Hockaday, David A. Cairns, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, David Stones, Nichola McWhirter, Surita Dalal, Andrew Rawstron, Piers Patten, Peter Hillmen
Journal: Blood
Blood (2024) 144 (Supplement 1): 585.
https://doi.org/10.1182/blood-2024-211449
Published: 2024
Journal Articles

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Ahmed Ludvigsen Al-Mashhadi, Mikkel Runason Simonsen, Elizabeth Smyth, Rose-Marie Amini, Bente Arboe, James R. Cerhan, Iman Chanchiri, Chan Y. Cheah, Jonathan Day, Toby A. Eyre, Anne Ortved Gang, Hervé Ghesquieres, Thomas M. Habermann, Eliza A. Hawkes, Steven R. Hwang, Ruxandra Irimia, Jennifer B Jørgensen, Arushi Khurana, Claire Maquet, Ng Layshe, Stephen S. Opat, Martin Bjerregård Pedersen, Christian Bjørn Poulsen, Alexandros Rampotas, Andreea Sima, Karin Ekstroem Smedby, Knut Smeland, Gita Thanarajasingam, Judith Trotman, Katharine Xing, Simon Østergaard, Diego Villa, Tarec Christoffer El-Galaly
Journal: Blood
Blood (2024) 144 (Supplement 1): 3019.
https://doi.org/10.1182/blood-2024-204328
Published: 2024
Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

David John Lewis, Mats Jerkeman, Lexy Sorrell, David Wright, Ingrid Glimelius, Annika Pasanen, Jacob Haaber Christensen, Karin Fahl Wader, Andrew J. Davies, Nick Morley, Christopher McNamara, Christian Bjørn Poulsen, Jon Riise, Kristina Sonnevi, Ingemar Lagerlöf, Cathy Burton, Surita Dalal, Andrew Rawstron, Ruth M de Tute, Victoria Allgar, Sree Aroori, Mark Warner, Brian Wainman, Claire Scully, Jeanette Sanders, Carsten Utoft Niemann, Helle Toldbod, Nicola Crosbie, Mark J Bishton, Toby A. Eyre, Simon Rule
Journal: Blood
Blood (2024) 144 (Supplement 1): 235.
https://doi.org/10.1182/blood-2024-199710
Published: 2024
Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Chiara Malinverni, Andrea Bernardelli, Ingrid Glimelius, Massimo Mirandola, Karin E. Smedby, Maria Chiara Tisi, Eva Giné, Alexandra Albertsson-Lindblad, Ana Marin-Niebla, Alice Di Rocco, Filipa Moita, Roberta Sciarra, Sandra Bašić-Kinda, Georg Hess, Anke Ohler, Christian W. Eskelund, Alessandro Re, Isacco Ferrarini, Arne Kolstad, Riikka Räty, Francesca Maria Quaglia, Toby A. Eyre, Greta Scapinello, Piero Maria Stefani, Lucia Morello, Luca Nassi, Stefan Hohaus, Simone Ragaini, Vittorio Ruggero Zilioli, Riccardo Bruna, Federica Cocito, Annalisa Arcari, Mats Jerkeman, Carlo Visco
Journal: Blood
Blood (2024) 144 (9): 1001–1009.
https://doi.org/10.1182/blood.2023023525
Published: 2024
Includes: Supplemental data
Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Catherine C. Coombs, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Ian W. Flinn, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Koji Izutsu, Wojciech Jurczak, William G. Wierda, Angely Loubert, Nalin Payakachat, Lisa M. Hess, Paolo Abada, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 6535.
https://doi.org/10.1182/blood-2023-186145
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Jonathon B. Cohen, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y. Cheah, Toby A. Eyre, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D. Nasta, Ian W. Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J. Alencar, David Lewis, Jennifer A. Woyach, Kami J. Maddocks, Krish Patel, Yucai Wang, Joanna M. Rhodes, Constantine S. Tam, John F. Seymour, Hirokazu Nagai, Julie M. Vose, Bita Fakhri, Marc S. Hoffmann, Francisco J. Hernandez-Ilizaliturri, Andrew D. Zelenetz, Anita Kumar, Talha Munir, Donald E. Tsai, Minna Balbas, Bin Liu, Amy S. Ruppert, Bastien Nguyen, Lindsey E. Roeker, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 981.
https://doi.org/10.1182/blood-2023-181627
Published: 2023
Journal Articles

Real-World Use and Outcomes of Therapies, Including Venetoclax-Based Treatments, after Discontinuation of a Covalent BTK Inhibitor in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nitin Jain, Toby A. Eyre, Katherine Winfree, Naleen Raj Bhandari, Manoj Khanal, Tomoko Sugihara, Paolo Abada, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 5152.
https://doi.org/10.1182/blood-2023-185758
Published: 2023
Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

William G. Wierda, Nirav N. Shah, Chan Yoon Cheah, David Lewis, Marc S. Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A. Eyre, Joanna M. Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S. Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J. Alencar, Manish Patel, John F. Seymour, Jennifer A. Woyach, Lindsey E. Roeker, Philip A. Thompson, Paolo Abada, Caleb Ho, Narasimha Marella, Chunxiao Wang, Amy S. Ruppert, Binoj Chandrasekharan Nair, Hui Liu, Donald E. Tsai, Paolo Ghia
Journal: Blood
Blood (2023) 142 (Supplement 1): 1737.
https://doi.org/10.1182/blood-2023-181108
Published: 2023
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Krish Patel, Julie M. Vose, Sunita D. Nasta, Jennifer R. Brown, Kami J. Maddocks, Jennifer A. Woyach, Nirav N. Shah, Bita Fakhri, Benoit Tessoulin, Shuo Ma, Deepa Jagadeesh, Ewa Lech-Maranda, Catherine C. Coombs, Manish Patel, Joanna M. Rhodes, Chaitra S Ujjani, Marc S. Hoffmann, Chan Y Cheah, Talha Munir, David Lewis, Lydia Scarfo, Toby A. Eyre, Alvaro J. Alencar, Jonathon B. Cohen, Andrew D. Zelenetz, Donald E. Tsai, Mei Li, Faith Bian, Paolo Abada, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1660.
https://doi.org/10.1182/blood-2023-180048
Published: 2023
Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 325.
https://doi.org/10.1182/blood-2023-185852
Published: 2023
Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Ahmed Ludvigsen Al-Mashhadi, Mikkel Runason Runason Simonsen, Chan Yoon Cheah, Rose-Marie Amini, Bente Arboe, James R. Cerhan, Iman Chanchiri, Michael Roost Clausen, Jonathan Day, Toby A. Eyre, Anne Ortved Gang, Herve Ghesquieres, Thomas M. Habermann, Eliza A Hawkes, Steven R. Hwang, Jennifer B Jørgensen, Arushi Khurana, Claire Maquet, Ng Layshe, Stephen S. Opat, Martin Bjerregård Pedersen, Christian Bjørn Poulsen, Alexandros Rampotas, Andreea Sima, Karin Ekstroem Smedby, Knut Smeland, Elizabeth Smyth, Gita Thanarajasingam, Judith Trotman, Katharine Xing, Simon Østergaard, Diego Villa, Tarec C El-Galaly
Journal: Blood
Blood (2023) 142 (Supplement 1): 4396.
https://doi.org/10.1182/blood-2023-173247
Published: 2023
Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Peter Hillmen, David Allan Cairns, Adrian John Clifton Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankaranarayana Paneesha, Christopher P. Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth M de Tute, Andrew Rawstron, Piers EM Patten, Talha Munir
Journal: Blood
Blood (2023) 142 (Supplement 1): 631.
https://doi.org/10.1182/blood-2023-178298
Published: 2023
Journal Articles

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Franck Morschhauser, Krish Patel, Sabela Bobillo, Raul Cordoba, Toby A. Eyre, Mark Bishton, Roch Houot, Hui-Lai Zhang, Liqun Zou, Wendy Osborne, Laura Gálvez-Carvajal, Catherine Thieblemont, Donald Yee, Andrea Knapp, Enkhtsetseg Purev, Haocheng Li, Vivian Chen, Karl L. Banta, Jason Sit, Emmanuel Bachy
Journal: Blood
Blood (2023) 142 (Supplement 1): 605.
https://doi.org/10.1182/blood-2023-174432
Published: 2023
Journal Articles

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, Mittal Shah, Toby Batten, David Tucker, Bryson Pottinger, Shankaranarayana Paneesha, Dima El-Sharkawi, Toby A. Eyre, Ho Pui Jeff Lam, Jiexin Zheng, Sarah Cook, David Granger, David Ahern, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2023) 142 (Supplement 1): 329.
https://doi.org/10.1182/blood-2023-188607
Published: 2023